While cannabis takes a breather from the capital markets roller
coaster ride that has characterized that sector lately,
psychedelics are in the news lately – and all the rage in the
capital markets. Junior pharmaceutical companies, specialized
clinics and Caribbean retreats are common water-cooler topics of
conversation these days among capital markets investors and
observers alike. To be sure, momentum is building and public
perception is changing in Canada and in some parts of the United
States toward reducing barriers to access for psychedelics. Low
enforcement priorities in Denver, Oakland and Santa Cruz, as well
as Oregon's proposed laws to regulate cultivation,
manufacture and sale of psilocybin products for medical purposes,
broadens the discussion. Today's momentum has been a long
time coming – particularly as a viable new option for mental
health treatment.
